The present invention relates to substituted pyrrolopyrimidine compounds general formula I: in which A, X, R
1
, R
2
, m and n are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20150166538A1
公开(公告)日:2015-06-18
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y
1
receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS
申请人:Lupin Limited
公开号:US20210052556A1
公开(公告)日:2021-02-25
Disclosed are compounds of the general formula (I),
wherein R
1
-R
3
are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
US9428504B2
申请人:——
公开号:US9428504B2
公开(公告)日:2016-08-30
[EN] 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR<br/>[FR] ANTAGONISTES DE 7-HYDROXY-SPIROPIPIPÉRIDINE INDOLINYLE DU RÉCEPTEUR P2Y1
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2014022349A1
公开(公告)日:2014-02-06
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.